Does the media refer more to IRTC or PRCT?

In the previous week, iRhythm Technologies had 6 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 11 mentions for iRhythm Technologies and 5 mentions for PROCEPT BioRobotics. iRhythm Technologies' average media sentiment score of 0.30 beat PROCEPT BioRobotics' score of -0.03 indicating that iRhythm Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRhythm Technologies 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral PROCEPT BioRobotics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PLSE or PRCT?

In the previous week, Pulse Biosciences had 4 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 9 mentions for Pulse Biosciences and 5 mentions for PROCEPT BioRobotics. Pulse Biosciences' average media sentiment score of 0.46 beat PROCEPT BioRobotics' score of -0.03 indicating that Pulse Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulse Biosciences 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PROCEPT BioRobotics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PRCT or TMDX?

In the previous week, TransMedics Group had 8 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 13 mentions for TransMedics Group and 5 mentions for PROCEPT BioRobotics. TransMedics Group's average media sentiment score of 0.52 beat PROCEPT BioRobotics' score of -0.03 indicating that TransMedics Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PROCEPT BioRobotics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral TransMedics Group 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, PRCT or ATRC?

AtriCure has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PROCEPT BioRobotics $308.05M 3.33 -$95.57M -$1.94 N/A AtriCure $534.53M 5.03 -$11.45M $0.21 251.62

Does the media prefer PRCT or ATRC?

In the previous week, PROCEPT BioRobotics had 1 more articles in the media than AtriCure. MarketBeat recorded 5 mentions for PROCEPT BioRobotics and 4 mentions for AtriCure. AtriCure's average media sentiment score of 0.22 beat PROCEPT BioRobotics' score of -0.03 indicating that AtriCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PROCEPT BioRobotics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral AtriCure 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PRCT or BFLY?

In the previous week, Butterfly Network had 13 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 18 mentions for Butterfly Network and 5 mentions for PROCEPT BioRobotics. Butterfly Network's average media sentiment score of 0.28 beat PROCEPT BioRobotics' score of -0.03 indicating that Butterfly Network is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PROCEPT BioRobotics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Butterfly Network 4 Very Positive mention(s) 1 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

PROCEPT BioRobotics (PRCT) Competitors

$17.90 -0.01 (-0.06%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$17.88 -0.02 (-0.12%)

As of 07:34 AM Eastern

Compare

PRCT vs. IRTC, PLSE, TMDX, ATRC, and BFLY

Should you buy PROCEPT BioRobotics stock or one of its competitors? PROCEPT BioRobotics's main competitors and comparable companies include iRhythm Technologies (IRTC), Pulse Biosciences (PLSE), TransMedics Group (TMDX), AtriCure (ATRC), and Butterfly Network (BFLY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does PROCEPT BioRobotics compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and PROCEPT BioRobotics (NASDAQ:PRCT) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

iRhythm Technologies currently has a consensus price target of $178.79, indicating a potential upside of 74.26%. PROCEPT BioRobotics has a consensus price target of $25.50, indicating a potential upside of 42.46%. Given iRhythm Technologies' stronger consensus rating and higher probable upside, analysts clearly believe iRhythm Technologies is more favorable than PROCEPT BioRobotics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94
PROCEPT BioRobotics	2 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.25

iRhythm Technologies has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market. Comparatively, PROCEPT BioRobotics has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market.

iRhythm Technologies has higher revenue and earnings than PROCEPT BioRobotics. iRhythm Technologies is trading at a lower price-to-earnings ratio than PROCEPT BioRobotics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$825.34M	4.10	-$44.55M	-$0.43	N/A
PROCEPT BioRobotics	$308.05M	3.33	-$95.57M	-$1.94	N/A

iRhythm Technologies has a net margin of -1.69% compared to PROCEPT BioRobotics' net margin of -32.53%. iRhythm Technologies' return on equity of 10.11% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-1.69%	10.11%	1.53%
PROCEPT BioRobotics	-32.53%	-30.62%	-22.10%

89.5% of PROCEPT BioRobotics shares are held by institutional investors. 1.0% of iRhythm Technologies shares are held by company insiders. Comparatively, 4.0% of PROCEPT BioRobotics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, iRhythm Technologies had 6 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 11 mentions for iRhythm Technologies and 5 mentions for PROCEPT BioRobotics. iRhythm Technologies' average media sentiment score of 0.30 beat PROCEPT BioRobotics' score of -0.03 indicating that iRhythm Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
PROCEPT BioRobotics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

iRhythm Technologies beats PROCEPT BioRobotics on 14 of the 17 factors compared between the two stocks.

How does PROCEPT BioRobotics compare to Pulse Biosciences?

Pulse Biosciences (NASDAQ:PLSE) and PROCEPT BioRobotics (NASDAQ:PRCT) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

77.0% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by insiders. Comparatively, 4.0% of PROCEPT BioRobotics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Pulse Biosciences has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market. Comparatively, PROCEPT BioRobotics has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market.

In the previous week, Pulse Biosciences had 4 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 9 mentions for Pulse Biosciences and 5 mentions for PROCEPT BioRobotics. Pulse Biosciences' average media sentiment score of 0.46 beat PROCEPT BioRobotics' score of -0.03 indicating that Pulse Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PROCEPT BioRobotics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pulse Biosciences currently has a consensus target price of $53.20, suggesting a potential upside of 6.44%. PROCEPT BioRobotics has a consensus target price of $25.50, suggesting a potential upside of 42.46%. Given PROCEPT BioRobotics' higher probable upside, analysts clearly believe PROCEPT BioRobotics is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
PROCEPT BioRobotics	2 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.25

Pulse Biosciences has higher earnings, but lower revenue than PROCEPT BioRobotics. Pulse Biosciences is trading at a lower price-to-earnings ratio than PROCEPT BioRobotics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	10,110.24	-$72.78M	-$1.18	N/A
PROCEPT BioRobotics	$308.05M	3.33	-$95.57M	-$1.94	N/A

PROCEPT BioRobotics has a net margin of -32.53% compared to Pulse Biosciences' net margin of -6,755.78%. PROCEPT BioRobotics' return on equity of -30.62% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%
PROCEPT BioRobotics	-32.53%	-30.62%	-22.10%

Summary

Pulse Biosciences beats PROCEPT BioRobotics on 9 of the 16 factors compared between the two stocks.

How does PROCEPT BioRobotics compare to TransMedics Group?

PROCEPT BioRobotics (NASDAQ:PRCT) and TransMedics Group (NASDAQ:TMDX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

TransMedics Group has a net margin of 22.69% compared to PROCEPT BioRobotics' net margin of -32.53%. TransMedics Group's return on equity of 15.88% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-32.53%	-30.62%	-22.10%
TransMedics Group	22.69%	15.88%	5.95%

TransMedics Group has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$308.05M	3.33	-$95.57M	-$1.94	N/A
TransMedics Group	$605.49M	4.51	$190.29M	$3.89	20.31

89.5% of PROCEPT BioRobotics shares are owned by institutional investors. Comparatively, 99.7% of TransMedics Group shares are owned by institutional investors. 4.0% of PROCEPT BioRobotics shares are owned by insiders. Comparatively, 6.9% of TransMedics Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, TransMedics Group had 8 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 13 mentions for TransMedics Group and 5 mentions for PROCEPT BioRobotics. TransMedics Group's average media sentiment score of 0.52 beat PROCEPT BioRobotics' score of -0.03 indicating that TransMedics Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PROCEPT BioRobotics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
TransMedics Group	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

PROCEPT BioRobotics currently has a consensus price target of $25.50, indicating a potential upside of 42.46%. TransMedics Group has a consensus price target of $121.00, indicating a potential upside of 53.16%. Given TransMedics Group's stronger consensus rating and higher possible upside, analysts clearly believe TransMedics Group is more favorable than PROCEPT BioRobotics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	2 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.25
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38

PROCEPT BioRobotics has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.94, indicating that its stock price is 94% more volatile than the broader market.

Summary

TransMedics Group beats PROCEPT BioRobotics on 16 of the 17 factors compared between the two stocks.

How does PROCEPT BioRobotics compare to AtriCure?

PROCEPT BioRobotics (NASDAQ:PRCT) and AtriCure (NASDAQ:ATRC) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

AtriCure has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$308.05M	3.33	-$95.57M	-$1.94	N/A
AtriCure	$534.53M	5.03	-$11.45M	$0.21	251.62

PROCEPT BioRobotics has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market. Comparatively, AtriCure has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

PROCEPT BioRobotics currently has a consensus price target of $25.50, suggesting a potential upside of 42.46%. AtriCure has a consensus price target of $53.30, suggesting a potential upside of 0.87%. Given PROCEPT BioRobotics' higher possible upside, equities analysts clearly believe PROCEPT BioRobotics is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	2 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.25
AtriCure	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58

AtriCure has a net margin of 1.85% compared to PROCEPT BioRobotics' net margin of -32.53%. AtriCure's return on equity of 2.34% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-32.53%	-30.62%	-22.10%
AtriCure	1.85%	2.34%	1.77%

89.5% of PROCEPT BioRobotics shares are held by institutional investors. Comparatively, 99.1% of AtriCure shares are held by institutional investors. 4.0% of PROCEPT BioRobotics shares are held by insiders. Comparatively, 4.0% of AtriCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, PROCEPT BioRobotics had 1 more articles in the media than AtriCure. MarketBeat recorded 5 mentions for PROCEPT BioRobotics and 4 mentions for AtriCure. AtriCure's average media sentiment score of 0.22 beat PROCEPT BioRobotics' score of -0.03 indicating that AtriCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PROCEPT BioRobotics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
AtriCure	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

AtriCure beats PROCEPT BioRobotics on 13 of the 16 factors compared between the two stocks.

How does PROCEPT BioRobotics compare to Butterfly Network?

PROCEPT BioRobotics (NASDAQ:PRCT) and Butterfly Network (NYSE:BFLY) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

Butterfly Network has lower revenue, but higher earnings than PROCEPT BioRobotics. Butterfly Network is trading at a lower price-to-earnings ratio than PROCEPT BioRobotics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$308.05M	3.33	-$95.57M	-$1.94	N/A
Butterfly Network	$97.61M	21.81	-$77.06M	-$0.29	N/A

PROCEPT BioRobotics has a net margin of -32.53% compared to Butterfly Network's net margin of -66.74%. PROCEPT BioRobotics' return on equity of -30.62% beat Butterfly Network's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-32.53%	-30.62%	-22.10%
Butterfly Network	-66.74%	-33.99%	-22.96%

PROCEPT BioRobotics has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market. Comparatively, Butterfly Network has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market.

PROCEPT BioRobotics presently has a consensus price target of $25.50, indicating a potential upside of 42.46%. Butterfly Network has a consensus price target of $8.54, indicating a potential upside of 6.84%. Given PROCEPT BioRobotics' higher possible upside, analysts clearly believe PROCEPT BioRobotics is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	2 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.25
Butterfly Network	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

89.5% of PROCEPT BioRobotics shares are held by institutional investors. Comparatively, 37.9% of Butterfly Network shares are held by institutional investors. 4.0% of PROCEPT BioRobotics shares are held by company insiders. Comparatively, 22.0% of Butterfly Network shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Butterfly Network had 13 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 18 mentions for Butterfly Network and 5 mentions for PROCEPT BioRobotics. Butterfly Network's average media sentiment score of 0.28 beat PROCEPT BioRobotics' score of -0.03 indicating that Butterfly Network is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PROCEPT BioRobotics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Butterfly Network	4 Very Positive mention(s)	1 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Butterfly Network beats PROCEPT BioRobotics on 8 of the 15 factors compared between the two stocks.

Get PROCEPT BioRobotics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRCT vs. The Competition

Export

Metric	PROCEPT BioRobotics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.03B	$5.44B	$7.19B	$13.40B
Dividend Yield	N/A	1.78%	2.53%	16.36%
P/E Ratio	-9.23	25.26	274.66	26.04
Price / Sales	3.33	68.51	559.19	72.92
Price / Cash	N/A	32.10	76.82	53.72
Price / Book	2.73	5.88	10.81	6.27
Net Income	-$95.57M	$146.72M	$3.50B	$382.01M
7 Day Performance	4.31%	-0.86%	-1.83%	-1.60%
1 Month Performance	-13.69%	-3.83%	-6.34%	-4.63%
1 Year Performance	-48.61%	1.73%	3.07%	-0.95%

PROCEPT BioRobotics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRCT PROCEPT BioRobotics	3.4199 of 5 stars	$17.90 -0.1%	$25.50 +42.5%	-48.5%	$1.03B	$308.05M	N/A	888	Analyst Upgrade
IRTC iRhythm Technologies	3.4352 of 5 stars	$109.09 -1.2%	$180.07 +65.1%	-42.7%	$3.64B	$825.34M	N/A	2,400	Analyst Forecast
PLSE Pulse Biosciences	2.502 of 5 stars	$50.50 +5.4%	$50.20 -0.6%	+150.7%	$3.39B	$350K	N/A	116	Analyst Forecast
TMDX TransMedics Group	4.6397 of 5 stars	$82.99 +4.0%	$121.10 +45.9%	-33.1%	$2.87B	$668.47M	21.33	898	News Coverage Analyst Forecast
ATRC AtriCure	2.6561 of 5 stars	$56.37 +2.2%	$53.30 -5.4%	+50.6%	$2.80B	$534.53M	268.44	1,350

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRCT) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PROCEPT BioRobotics (PRCT) Competitors

PRCT vs. IRTC, PLSE, TMDX, ATRC, and BFLY

How does PROCEPT BioRobotics compare to iRhythm Technologies?

Summary

How does PROCEPT BioRobotics compare to Pulse Biosciences?

Summary

How does PROCEPT BioRobotics compare to TransMedics Group?

Summary

How does PROCEPT BioRobotics compare to AtriCure?

Summary

How does PROCEPT BioRobotics compare to Butterfly Network?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRCT vs. The Competition

PROCEPT BioRobotics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PROCEPT BioRobotics (PRCT) Competitors

PRCT vs. IRTC, PLSE, TMDX, ATRC, and BFLY

How does PROCEPT BioRobotics compare to iRhythm Technologies?

Do analysts prefer IRTC or PRCT?

Which has more risk & volatility, IRTC or PRCT?

Which has better valuation and earnings, IRTC or PRCT?

Is IRTC or PRCT more profitable?

Do insiders & institutionals believe in IRTC or PRCT?

Does the media refer more to IRTC or PRCT?

Summary

How does PROCEPT BioRobotics compare to Pulse Biosciences?

Do institutionals and insiders hold more shares of PLSE or PRCT?

Which has more volatility and risk, PLSE or PRCT?

Does the media refer more to PLSE or PRCT?

Do analysts prefer PLSE or PRCT?

Which has better earnings and valuation, PLSE or PRCT?

Is PLSE or PRCT more profitable?

Summary

How does PROCEPT BioRobotics compare to TransMedics Group?

Is PRCT or TMDX more profitable?

Which has stronger valuation and earnings, PRCT or TMDX?

Do institutionals & insiders believe in PRCT or TMDX?

Does the media prefer PRCT or TMDX?

Do analysts rate PRCT or TMDX?

Which has more risk & volatility, PRCT or TMDX?

Summary

How does PROCEPT BioRobotics compare to AtriCure?

Which has preferable earnings & valuation, PRCT or ATRC?

Which has more risk and volatility, PRCT or ATRC?

Do analysts rate PRCT or ATRC?

Is PRCT or ATRC more profitable?

Do insiders & institutionals hold more shares of PRCT or ATRC?

Does the media prefer PRCT or ATRC?

Summary

How does PROCEPT BioRobotics compare to Butterfly Network?

Which has higher valuation and earnings, PRCT or BFLY?

Is PRCT or BFLY more profitable?

Which has more risk and volatility, PRCT or BFLY?

Do analysts recommend PRCT or BFLY?

Do institutionals and insiders hold more shares of PRCT or BFLY?

Does the media favor PRCT or BFLY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRCT vs. The Competition

PROCEPT BioRobotics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools